세계의 암 생물학적 치료 시장

The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.

The monoclonal antibodies segment of biological therapies market for cancer is expected to grow from $88.1 billion in 2025 and is projected to reach $126.5 billion by the end of 2030, at a CAGR of 7.5% during the forecast period of 2025 to 2030.

The CAR T-cell therapy segment of biological therapies market for cancer is expected to grow from $23.4 billion in 2025 and is projected to reach $34.1 billion by the end of 2030, at a CAGR of 7.8% during the forecast period of 2025 to 2030.

Report Scope

This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.

The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.

Report Includes

• 43 data tables and 53 additional tables
• An analysis of the global markets for biological therapies for cancer treatment and related technologies
• Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
• Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
• Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
• Impact analysis of the U.S. tariff laws on the market
• Insights derived from Porter's Five Forces model, as well as global supply chain
• A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
• Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
• A relevant patent analysis, featuring key granted and published patents
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Technological Advances
• Market Dynamics and Growth Factors
• Segmental Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Key Modalities and Mechanisms of Action
• Porter's Five Forces Model
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Competition in the Industry
• Threat of Substitutes
• Macroeconomic Factors Analysis
• Aging Population Driving Cancer Incidence and Demand for Biologics
• Rising Healthcare Expenditures and Oncology Drug Spending
• Impact of the U.S. Tariff Scenario
• Pricing Strategies for Cancer Biologics
• Value-Based Pricing
• Premium Pricing for Innovation
• Indication-Based Pricing
• Market Access and Tiered Pricing
• Competitive Benchmarking
• Cancer Drug Costs
• Overview of Biosimilars
• Biosimilars and Costs of Cancer Drugs
• Biosimilars in India and China
• Biosimilars in Europe
• Issues with Biosimilars

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Global Cancer Incidence
• Advances in Immuno-Oncology and Targeted Therapies
• Shift Towards Personalized and Precision Medicine
• Market Restraints
• High Treatment Costs
• Stringent Manufacturing and Regulatory Requirements
• Market Opportunities
• Expanding Indications for Approved Biologics
• Technological Advances in Biologics Manufacturing

Chapter 4 Regulatory Landscape

• Biological Therapies for Cancer Industry Regulatory Scenario
• Overview
• U.S.
• EU
• Japan
• China
• India
• Medicare Coverage and Reimbursement for Cancer Care

Chapter 5 Emerging Technologies and Developments

• Overview
• Next-Generation Antibody-Drug Conjugates (ADCs)
• Bispecific and Multispecific Antibodies
• Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
• Allogeneic ("Off-the-Shelf") Cell Therapies
• Artificial Intelligence (AI) in Biological Cancer Therapies

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis for Biological Therapies for Cancer by Product Type
• Monoclonal Antibodies
• Vaccines
• CAR T-cell Therapy
• Cancer Growth Blockers
• Immune Checkpoint Inhibitors
• Other (Blood Cell Growth Factors, Cytokines)
• Market Analysis of Biological Therapies for Cancer by Cancer Type
• Epidemiology by Cancer Type/Site
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Other (Blood, Skin, Ovarian, Rare Cancer)
• Geographic Breakdown
• Global Biosimilars Market by Region
• Market Size and Forecast
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Cancer Clinical Trials and Biologics in Development

• Overview
• Key Pipeline Drugs by Company

Chapter 8 Competitive Landscape

• Overview
• Biological Therapy for Cancer Market: Major Players

Chapter 9 Appendix

• Methodology
• References
• Abbreviations
• Company Profiles
• AMGEN INC.
• ASTRAZENECA
• BAYER AG
• BIONTECH SE
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GSK PLC
• INCYTE
• INNATE PHARMA INC.
• JOHNSON & JOHNSON
• LILLY USA LLC
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• SANOFI